ography and Effect of Trastuzumab

Download pose: This study sought to evaluate the reproducibility of [C]choline-positron emission tomogand the effect of trastuzumab in breast cancer. erimental Design: Twenty-one patients with newly diagnosed and recurrent breast cancer stage IIa baseline dynamic [C]choline-PET scan, 10 patients had a second [C]choline-PET scan to ne reproducibility, and 6 patients had a second scan within a month after trastuzumab. Analysis ]choline uptake was measured as the semiquantitative standardized uptake value at 30 and 60 minSUV30 and SUV60), and quantitatively as the net irreversible retention of the radiotracer at steadyKi) and plasma to tissue exchange at 60 minutes (IRF60min). ults: Breast tumor lesions in all patients were visualized by [C]choline PET. The difference in versus normal tissue uptake was significant for SUV30, SUV60, Ki, and IRF60 minutes (Wilcoxon 001). At 60 minutes postinjection, 15.1 ± 2.16% of plasma radioactivity was due to unmetabolized holine radioactivity. [C]Choline uptake was reproducible in breast tumor lesions (r = 0.9 for 0.9 for Ki, and 0.8 for IRF60). Early responses to trastuzumab measured by [C]choline-PET were cant in three lesions occurring in two patients who responded clinically. signifi Conclusions: [C]Choline-PET uptake variables can be reproducibly assessed. Initial studies show that trastuzumab decreases [C]choline uptake. Clin Cancer Res; 16(16); 4236–45. ©2010 AACR.